Multi-Objective AI for Drug Discovery

Thoth Biosimulations provides AI-driven computational drug discovery services to support the design and optimization of small-molecule therapeutics. Using our proprietary platform, AI-MedCraft™, we help partners generate new candidate molecules, improve existing leads, and address challenges such as potency, selectivity, and developability.

In addition to collaborative research services, we also provide secure cloud-based access to AI-MedCraft, allowing organizations to run molecular design campaigns independently within their own discovery programs.

Getting started is simple. Contact us at (customercare@thothbiosimulations.ca) to discuss your project, including your biological target, available structural data, and design objectives. We then evaluate the scope of the project and propose a computational strategy tailored to your discovery program.

For organizations interested in using AI-MedCraft independently, we also provide secure cloud access to the platform.

Traditional drug discovery often optimizes molecular properties sequentially, leading to costly trade-offs between potency, safety, and developability. Thoth Biosimulations takes a different approach by applying AI-driven multi-objective optimization to evaluate these properties simultaneously within a single design cycle.

This approach enables the generation of balanced drug candidates and can help rescue promising compounds that face developability challenges.

You can reach us through the contact form on our website or by email (customercare@thothbiosimulations.ca). We are happy to discuss potential collaborations with academic groups, biotech companies, and pharmaceutical partners interested in AI-driven drug discovery.

Our pricing depends on the scope and nature of the engagement. We offer both project-based computational discovery services and licensed access to the AI-MedCraft platform through a secure cloud environment. Pricing is tailored to the needs of each partner and the scale of the discovery program.

We work closely with our partners to integrate computational design into their discovery programs. Projects typically begin with defining design objectives and constraints, followed by iterative molecular design and analysis. Our goal is to provide actionable insights and prioritized candidate molecules that guide experimental validation and accelerate discovery decisions.

We support a wide range of early-stage discovery activities, including lead generation, lead optimization, scaffold exploration, and the improvement of compounds with developability limitations. Our platform is particularly effective for projects that require balancing multiple molecular properties simultaneously.

Yes. In addition to generating new molecules, AI-MedCraft can optimize existing compounds by improving properties such as potency, selectivity, solubility, or other developability factors while preserving key molecular interactions.

While structural information such as protein structures can be very helpful, it is not always required. AI-MedCraft can operate with different types of input data, including known ligands, pharmacophore models, or other molecular information that helps guide the design process.

AI-MedCraft focuses on the design and optimization of small-molecule drug candidates. The platform can generate novel chemical structures, explore new chemical space around known compounds, and refine existing molecules.

Yes. Synthetic accessibility is incorporated into the design process. AI-MedCraft evaluates synthesizability alongside biological and physicochemical properties to prioritize molecules that are more likely to be practical for medicinal chemistry and experimental testing.

Yes. AI-MedCraft is designed to complement existing discovery workflows. The platform can incorporate structural data, ligand information, or experimental insights to guide molecular design within ongoing research programs.

We take data security and confidentiality seriously. Projects and platform access are conducted within secure computational environments designed to protect partner data and intellectual property. Organizations using AI-MedCraft through the cloud platform operate within protected infrastructure to ensure data privacy.

We collaborate with academic research groups, biotechnology companies, and pharmaceutical organizations seeking advanced computational approaches to accelerate drug discovery and optimize candidate molecules.